Supplements’ Non-GMO Journey Will Hit Supply Chain Bumps, Potential Regulatory Detours
This article was originally published in The Tan Sheet
Supplement firms eyeing the non-GMO route should start with simple formulas, build lines slowly and keep likeminded business partners, say experts about the challenges and benefits of purging bioengineered substances from products.
You may also be interested in...
During first-ever congressional hearing on federal policies for lawful use of cannabis, House Energy and Commerce Health Subcommittee Chairwoman Anna Eschoo says with $2m appropriated to develop a regulation on CBD’s use in non-drug products during, FDA should deliver.